Tipsheet
What matters at India’s listed companies
Earnings · Pharmaceuticals · Micro cap

Mercury Labs profit dives 69% in Q1 as revenue slips 12%

Net profit plunges to ₹29.78 lakh from ₹96.76 lakh a year ago; auditors issue unmodified report.

1 earlier story on Mercury Laboratories Ltd.
Mkt cap₹97.56 cr
P/E20.19×
ROE5.87%
Debt / eq.0.08
Div yld0.43%
69% YoY decline in Q1 net profit

What's new

  • Revenue fell 12% YoY to ₹15.96 crore in Q1 FY27.
  • Net profit dropped 69% to ₹29.78 lakh from ₹96.76 lakh.
  • Auditors gave an unmodified report on the unaudited results.

Why this matters

For a nano-cap pharma with a ₹98 crore market cap, a 69% profit crash signals serious near-term pressure on margins or demand. The lack of management commentary means investors have no explanation beyond the bare numbers.

What we're watching

  • Whether Q2 shows any recovery or further deterioration.
  • Any cost or revenue guidance from management in the next call.
  • Impact on the stock's already thin liquidity at current market cap.

The full read

Mercury Laboratories reported a brutal first quarter. Net profit plunged 69% to ₹29.78 lakh from ₹96.76 lakh a year earlier, on a 12% revenue decline to ₹15.96 crore. The auditors issued a clean report (no qualification) but the absence of management commentary leaves investors guessing. For a nano-cap pharma with a ₹98 crore market cap and a trailing P/E of 20x, this kind of earnings contraction raises real questions about demand and cost control. The next quarter will tell if this was a one-off or the start of a trend.

Questions answered

What caused Mercury's sharp profit decline?
The filing does not provide a reason. The company only reported the numbers without commentary, so the drop could be from seasonal weakness, higher costs, or lower realizations.
Is the auditor's report clean?
Yes. The statutory auditors conducted a limited review and issued an unmodified (clean) report, meaning no red flags in the accounting.
How does Mercury's valuation look after this quarter?
With a trailing P/E of 20.2x and market cap of ₹98 crore, the stock still trades at a premium to its earnings base, which just shrank 69%.
Did the board declare a dividend or buyback?
No. The board only approved the quarterly results; no dividend or other corporate action was announced.
Mentioned: Mercury Laboratories · Q1 FY27 · ₹15.96 crore revenue · ₹29.78 lakh profit
Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Company snapshot

Mercury Laboratories Ltd.

Pharmaceuticals
₹100 cr
P/E 24.07×

Latest quarter · Jun 2026

Sales₹16 cr
Net profit₹0 cr
Op. margin+7.5%
EPS₹2.48

Strength & growth

Debt / equity0.08×
Current ratio2.66×
Sales CAGR+4.5%
EPS CAGR+1.8%
  1. 25 Jul 2026 · 12:17 PM IST Mercury Labs profit dives 69% in Q1 as revenue slips 12%
  2. 3d ago Mercury Labs net profit plunges 69% as revenue slips in Q1